Anosmia. Anosmia
Conditions
Interventions
Intervention 1: Intervention group: Mometasone nasal spray 0.05% by Sina daru pharmaceutical company as one puff every 12 hours for one month. Intervention 2: Control group: sodium chloride nasal spr
Sponsors
Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Inclusion criteria are adults over the age of 18 with a diagnosis of COVID-19 based on clinical criteria (presence of any symptoms of cough, shortness of breath, fever, and CT scan of the lung for evidence of involvement consistent with COVID-19 infection) or PCR and had an olfactory dysfunction ( reduced or loss of sense of smell) for two weeks
Exclusion criteria
Exclusion criteria: Pregnancy and lactation History of olfactory dysfunction Taking drugs that affect the olfactory disorders Corticosteroids chronic use Nasal anatomic dysfunction Existence of dry ducts or nasal bleeding Existence of herpetic lesion Dissatisfaction with participating in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Olfactory symptoms improvement. Timepoint: before intervention and one month later. Method of measurement: Pennsylvania score and Visual Analogue Scale.;Safety of mometasone nasal spray. Timepoint: weekly during the study. Method of measurement: patient tolerability. | — |
Secondary
| Measure | Time frame |
|---|---|
| Olfactory symptoms improvement duration. Timepoint: End of treatment. Method of measurement: Patient interview.;Determination of effective patient factors on olfactory dysfunction. Timepoint: study period. Method of measurement: patient interview. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMonireh Ghazaeian
Mazandaran University of Medical Sciences
Outcome results
None listed